Your browser is no longer supported. Please, upgrade your browser.
CELG Celgene Corporation daily Stock Chart
Celgene Corporation
IndexS&P 500 P/E16.37 EPS (ttm)5.20 Insider Own0.20% Shs Outstand748.30M Perf Week-0.69%
Market Cap63.68B Forward P/E8.33 EPS next Y10.21 Insider Trans-4.31% Shs Float722.46M Perf Month6.68%
Income4.12B PEG0.86 EPS next Q2.10 Inst Own78.20% Short Float2.13% Perf Quarter-4.33%
Sales13.58B P/S4.69 EPS this Y109.10% Inst Trans-0.07% Short Ratio2.28 Perf Half Y-17.10%
Book/sh6.91 P/B12.32 EPS next Y19.63% ROA- Target Price112.58 Perf Year-37.57%
Cash/sh6.33 P/C13.43 EPS next 5Y19.07% ROE- 52W Range74.13 - 147.17 Perf YTD-18.46%
Dividend- P/FCF- EPS past 5Y25.80% ROI20.00% 52W High-42.18% Beta1.29
Dividend %- Quick Ratio2.40 Sales past 5Y18.70% Gross Margin96.40% 52W Low14.80% ATR1.52
Employees7467 Current Ratio2.50 Sales Q/Q19.40% Oper. Margin- RSI (14)65.72 Volatility1.42% 1.77%
OptionableYes Debt/Eq3.92 EPS Q/Q-4.20% Profit Margin- Rel Volume0.70 Prev Close85.34
ShortableYes LT Debt/Eq3.92 EarningsJul 26 BMO Payout- Avg Volume6.76M Price85.10
Recom2.30 SMA204.14% SMA506.07% SMA200-11.44% Volume4,749,543 Change-0.28%
Jun-18-18Upgrade Standpoint Research Hold → Buy
May-29-18Reiterated SunTrust Hold $106 → $96
May-23-18Upgrade Bernstein Mkt Perform → Outperform
May-23-18Downgrade Argus Buy → Hold
May-07-18Downgrade RBC Capital Mkts Top Pick → Outperform
Apr-13-18Resumed Morgan Stanley Equal-Weight $93
Mar-26-18Reiterated Goldman Sell $97 → $85
Mar-21-18Resumed JP Morgan Overweight $110
Feb-28-18Reiterated Stifel Buy $130 → $128
Feb-28-18Downgrade SunTrust Buy → Hold
Feb-13-18Upgrade Barclays Equal Weight → Overweight $105
Jan-26-18Reiterated SunTrust Buy $127 → $139
Jan-05-18Downgrade BofA/Merrill Buy → Neutral
Dec-27-17Downgrade Bernstein Outperform → Mkt Perform
Dec-22-17Reiterated Stifel Buy $149 → $130
Dec-08-17Upgrade Atlantic Equities Neutral → Overweight
Oct-27-17Upgrade Morgan Stanley Underweight → Equal-Weight
Oct-27-17Reiterated SunTrust Buy $156 → $127
Oct-27-17Reiterated Barclays Equal Weight $135 → $105
Oct-27-17Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jul-19-18 08:46AM  The 3 Worst Healthcare Stocks of 2018 (So Far) Motley Fool
07:00AM  Are CEOs Really Worth What Theyre Paid? InvestorPlace
Jul-18-18 09:12PM  New Drugs and Expected Growth Could Trigger a Recovery for Celgene Stock InvestorPlace
10:32AM  Big money rolls in as GOP challenger pressures NJ Democrat Menendez for traditionally safe Senate seat CNBC
06:59AM  Biotech's Coming Back to Life: Cramer's 'Off the Charts'
Jul-17-18 07:01PM  Cramer's charts suggest big-name biotech stocks Gilead an... CNBC Videos
07:00PM  Charts: Gilead and Celgene have more room to run CNBC Videos
06:45PM  Cramer's charts suggest big-name biotech stocks Gilead and Celgene have more room to run CNBC
Jul-15-18 06:32AM  3 Best Big Pharma Stocks to Buy for the 2nd Half of 2018 Motley Fool
Jul-13-18 07:31AM  Why Celgene Corporation Lost 23.9% of Its Value Halfway Through 2018 Motley Fool
06:00AM  Biotech Celgene's Stock Seen Rebounding 14% Investopedia
Jul-12-18 05:23PM  Ex-Drug CEO Running for Senate Seat Attacked by Old Industry Foe Bloomberg
02:59PM  Nohla adds $11 million in funding and three new investors American City Business Journals
10:11AM  3 Real Risks That Could Make You Reconsider Buying Celgene Stock InvestorPlace
12:00AM  Many Drugmakers Ignore Trumpand Raise Prices Anyway Bloomberg
Jul-11-18 07:05PM  Top 5 Biotech Stocks for 2018 Investopedia
04:49PM  Celgene Reports Positive Data on Tecentriq, Abraxane Study Zacks
03:11PM  Russian Drugmaker Granted License to Produce Celgene Copycat Fortune
09:41AM  Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More Zacks
08:00AM  Today's Research Reports on Trending Tickers: Galapagos and Celgene ACCESSWIRE
Jul-10-18 04:06PM  Dow, S&P 500 Gain For Fourth Day; Nasdaq Ends Flat
02:50PM  Celgene, Acceleron Report Positive Data on Thalassemia Drug Zacks
11:52AM  Upbeat Celgene Data Not Enough to Lift Biotech Sector
11:32AM  Stocks - PepsiCo, Celgene Gain in Pre-Market, EBay Falls, OncoCyte Soars
09:24AM  Stocks to Watch: Microsoft, Pepsi, Amazon, Walmart, Disney, eBay, Smucker, Electronic Arts, Celgene The Wall Street Journal
08:11AM  Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage Benzinga
07:43AM  Celgene reports positive results in late-stage trial of treatment for breast cancer MarketWatch
07:33AM  Jim Cramer Shares His Thoughts On Home Depot, Celgene And More Benzinga
07:30AM  Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassion130 Study Business Wire
Jul-09-18 06:51PM  Cramer's lightning round: Calling bottom in Southwest Airlines despite oil trends CNBC
06:13PM  [$$] Celgene, Acceleron Say Trial on Blood-Disorder Drug Yields Positive Results The Wall Street Journal
05:13PM  Celgene, Acceleron shares rise on blood-disorder drug study MarketWatch
04:52PM  Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III BELIEVE Study in Adults with Transfusion-Dependent Beta-Thalassemia Business Wire
08:18AM  Celgene (CELG) Down 21% So Far in 2018: What Lies Ahead? Zacks
06:00AM  4 Biotechs on Verge of Big Breakouts Investopedia
Jul-08-18 07:16PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga
03:15PM  Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far Motley Fool
09:30AM  3 Top Biotech Stocks to Buy for the 2nd Half of 2018 Motley Fool
Jul-06-18 05:29PM  Is health care the ultimate hideout trade? CNBC Videos
03:49PM  How Prosper Trading Academy CEO Is Trading Celgene Bloomberg Video
03:49PM  How Prosper Trading Academy CEO Is Trading Celgene Bloomberg
03:13PM  Why Biotech Stocks Rallied on Biogen's Alzheimer's Test Zacks
12:26PM  Biotech Stocks Rally on Biogen's Landmark Test
11:17AM  Celgene Is Turning Up as Bulls Gain Control
06:00AM  5 Bargain Biotechs Poised for Big Short-Term Gains Investopedia
Jul-05-18 08:42PM  Corrections & Amplifications The Wall Street Journal
06:17PM  Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More Zacks
02:40PM  Drug pricing debate could heat up in July CNBC Videos
12:25PM  A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year Benzinga
10:21AM  It May Be Imperfect, but Celgenes Growth Is Worth Taking Note of InvestorPlace
08:47AM  3 Best Biotech Acquisitions of 2018 (So Far) Motley Fool
Jul-04-18 08:00PM  [$$] Why July Is a Risky Month for Drug Price Backlash The Wall Street Journal
Jul-03-18 10:45PM  3 Reasons BeiGene Needs to Be on Your Radar Motley Fool
06:01AM  The 5 Biggest Blockbuster Drugs of 2024, and the Companies Poised to Profit From Them Motley Fool
Jul-02-18 08:20AM  Today's Research Reports on Trending Tickers: Geron and Celgene ACCESSWIRE
08:00AM  7 Favorite Picks of a $40 Billion Portfolio Star Investopedia
07:30AM  Celgene Corporation to Announce Second Quarter 2018 Results on July 26, 2018 Business Wire
Jul-01-18 08:00AM  Pharma's 2 Biggest Setbacks in 2018 Motley Fool
Jun-30-18 07:17AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
07:16AM  Celgene Investors Breathe a Sigh of Relief After Acceleron's Success Motley Fool
07:00AM  Wall Street Has Given Up on These 3 Stocks, and You Might Profit From That Mistake Motley Fool
Jun-29-18 05:00PM  Acceleron Pharma Soars On Celgene-Partnered Anemia Treatment Investor's Business Daily
02:54PM  Celgene's Luspatercept Meets Primary Endpoint in the Study Zacks
12:07PM  A Huge Win Sends Acceleron Pharma Shares Soaring 42% Motley Fool
11:10AM  Acceleron Pharma Rallies After Phase 3 MDS Data, But Goldman Sachs Still Isn't Buying Benzinga
09:37AM  Stocks to Watch: Nike, 21st Century Fox, Goldman Sachs, Morgan Stanley, Citigroup, Convergys The Wall Street Journal
09:11AM  4 Biotech Stocks to Bet on in the Second Half of 2018 Zacks
08:30AM  Ron Squarer's risk-taking pays off at Array American City Business Journals
08:11AM  Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos Benzinga
08:10AM  Today's Research Reports on Trending Tickers: Celgene and Rite Aid ACCESSWIRE
Jun-28-18 04:30PM  Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III MEDALIST Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes Business Wire
Jun-27-18 01:30PM  8 Stocks Poised To Lead In An Uncertain Market Investopedia
11:32AM  Agios Out-Licenses China Rights to Leukemia Drug Tibsovo Zacks
11:04AM  [$$] Nike, Facebook, Mitsubishi, and Other Global Picks
09:08AM  The problem with high drug prices isn't 'foreign freeloading,' it's the patent system CNBC
Jun-26-18 03:37PM  Enbridge, Celgene, Intuitive Surgical & Financials CNBC Videos
Jun-25-18 03:36PM  20 Massively Underpriced Stocks Wall Street Expects to Soar InvestorPlace
10:46AM  Celgene Price Weakness in Rear-View Mirror
Jun-24-18 06:32AM  Long-Term Investors Take Note -- These 5 Big Pharma Companies Have the Best Pipelines Motley Fool
Jun-23-18 10:21AM  Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives Benzinga
Jun-22-18 03:06PM  Celgene sues pharma with Durham ops American City Business Journals
07:00AM  2 Incredibly Cheap Value Stocks to Buy Now Motley Fool
Jun-21-18 08:00AM  Complimentary Technical Snapshots on Celgene and Three More Biotech Stocks ACCESSWIRE
06:30AM  Why I'm Bullish on the Riskiest Big Biotech Stock on the Market Motley Fool
Jun-19-18 04:30PM  Celgene Corporation Announces Appointment of Jonathan Biller as Executive Vice President and General Counsel Following the Departure of Gerald F. Masoudi Business Wire
04:02PM  5 Top Stock Trades for Wednesday Morning InvestorPlace
01:25PM  CVS will offer home delivery of prescriptions Yahoo Finance Video
08:16AM  Better Buy: Celgene Corporation vs. Merck Motley Fool
Jun-18-18 11:45AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Jun-17-18 12:03PM  Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming Motley Fool
Jun-15-18 07:03PM  Cramer's lightning round: Tandem Diabetes is one of the h... CNBC Videos
06:49PM  Cramer's lightning round: Tandem Diabetes is one of the hottest stocks I've ever seen CNBC
10:26AM  MARKETS: Here's why stocks are dropping right now Yahoo Finance Video
09:46AM  Should You Buy Celgene Stock? Motley Fool
09:11AM  Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant Zacks
Jun-14-18 08:20AM  Report: Developing Opportunities within Equinix, Sonus Networks, Celgene, National Grid, Atlas Air Worldwide, and Copa Holdings, S.A. Future Expectations, Projections Moving into 2018 GlobeNewswire
Jun-13-18 12:00AM  [$$] Celgene admits self-inflicted error over MS drug Financial Times
Jun-12-18 08:42AM  The Zacks Analyst Blog Highlights: Disney, Caterpillar, MetLife, Celgene and Northrop Grumman Zacks
Jun-11-18 06:01PM  Ex-Juno leader becomes CEO of Alder BioPharmaceuticals ahead of migraine drug launch American City Business Journals
11:43AM  Top Research Reports for Disney, Caterpillar & MetLife Zacks
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for multiple hematological cancers. The company has agreement with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; Prothena Corporation plc; Zymeworks Inc.; and Evotec AG, as well as strategic collaboration with Skyhawk Therapeutics, Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BARKER RICHARD WDirectorJun 17Option Exercise0.001,000012,846Jun 18 04:00 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033400Jun 18 04:00 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033400Jun 18 04:00 PM
LOUGHLIN JAMES JDirectorJun 17Option Exercise0.00334037,436Jun 18 04:00 PM
MARIO ERNESTDirectorJun 17Option Exercise0.00334056,413Jun 18 04:00 PM
Haller Julia ADirectorJun 15Option Exercise0.0037501,250Jun 15 04:57 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375056,079Jun 15 04:23 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.0037501,050Jun 15 04:17 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 15 04:16 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.002,441037,102Jun 15 04:13 PM
Friedman Michael ADirectorJun 15Option Exercise0.002,41300Jun 15 04:12 PM
Haller Julia ADirectorJun 14Option Exercise0.003000875Jun 15 04:57 PM
MARIO ERNESTDirectorJun 14Option Exercise0.00300055,704Jun 15 04:23 PM
BONNEY MICHAEL WDirectorJun 14Option Exercise0.003000675Jun 15 04:17 PM
CASEY MICHAEL DDirectorJun 14Option Exercise0.0030000Jun 15 04:16 PM
LOUGHLIN JAMES JDirectorJun 14Option Exercise0.00300034,661Jun 15 04:13 PM
Friedman Michael ADirectorJun 14Option Exercise0.0030000Jun 15 04:12 PM
COX CARRIE SMITHDirectorJun 12Option Exercise0.006,200030,080Jun 14 04:35 PM
CASEY MICHAEL DDirectorJun 07Option Exercise30.0127,750832,77827,750Jun 11 04:06 PM
CASEY MICHAEL DDirectorJun 07Sale78.7713,0001,024,0100Jun 11 04:06 PM
LOUGHLIN JAMES JDirectorJun 04Option Exercise30.0127,750832,77852,111Jun 05 04:15 PM
LOUGHLIN JAMES JDirectorJun 04Sale78.9617,7501,401,54034,361Jun 05 04:15 PM
Masoudi GeraldSEE REMARKSJun 01Option Exercise0.0015,000020,235Jun 05 04:09 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 09Buy82.601,20899,784187,316May 17 04:08 PM
Curran TerrieMay 04Option Exercise0.002,50007,507May 08 04:56 PM
VESSEY RUPERTMay 04Option Exercise0.0078103,731May 08 04:36 PM
KELLOGG PETER NMay 04Option Exercise0.003,500050,831May 08 04:34 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 04Option Exercise0.003,5000187,627May 08 04:30 PM
LOUGHLIN JAMES JDirectorMar 12Option Exercise27.189,250251,41533,611Mar 13 04:22 PM
LOUGHLIN JAMES JDirectorMar 12Sale92.019,250851,09324,361Mar 13 04:22 PM
MARIO ERNESTDirectorFeb 23Sale94.4913,3701,263,29855,404Feb 26 04:11 PM
KAPLAN GILLADirectorFeb 20Sale94.839,250877,17876,301Feb 20 05:02 PM
Smith Scott AndrewSee RemarksFeb 17Option Exercise0.007,283051,748Feb 20 05:03 PM
KELLOGG PETER NSee RemarksFeb 17Option Exercise0.007,283049,660Feb 20 05:03 PM
Alles Mark JSee RemarksFeb 17Option Exercise0.007,2830186,187Feb 20 05:00 PM
KAPLAN GILLADirectorFeb 15Option Exercise27.189,250251,41594,801Feb 20 05:02 PM
KAPLAN GILLADirectorFeb 15Sale95.999,250887,89885,551Feb 20 05:02 PM
Alles Mark JSee RemarksFeb 08Buy91.903,260299,594178,904Feb 08 04:47 PM
VESSEY RUPERTSee remarksFeb 02Option Exercise0.005,62305,623Feb 05 04:39 PM
Smith Scott AndrewSee RemarksDec 19Option Exercise0.003,410046,233Dec 20 04:05 PM
KELLOGG PETER NSee RemarksDec 19Option Exercise0.003,410044,145Dec 20 04:04 PM
Curran TerrieSee remarksDec 19Option Exercise0.001,76505,690Dec 20 04:03 PM
Alles Mark JSee RemarksDec 19Option Exercise0.004,5500177,738Dec 20 04:02 PM
KAPLAN GILLADirectorDec 05Option Exercise24.979,250230,92685,551Dec 06 04:45 PM
MARIO ERNESTDirectorOct 30Option Exercise31.8013,600432,41271,024Nov 01 04:11 PM
KELLOGG PETER NSee RemarksOct 27Option Exercise0.002,100041,823Oct 31 04:10 PM
HUGIN ROBERT Jsee remarksOct 26Option Exercise31.8162,0201,972,5501,060,106Oct 26 04:44 PM
Curran TerrieSee remarksSep 25Sale143.891,727248,4983,925Sep 26 04:29 PM
KAPLAN GILLADirectorSep 12Option Exercise33.889,250313,39085,551Sep 14 04:35 PM
KAPLAN GILLADirectorSep 12Sale141.569,2501,309,43076,301Sep 14 04:35 PM
CASEY MICHAEL DDirectorSep 05Sale139.039,2501,286,0280Sep 06 06:53 PM
MARIO ERNESTDirectorAug 10Sale130.5218,5062,415,40369,424Aug 14 04:53 PM
KAPLAN GILLADirectorAug 02Sale134.527,5001,008,90076,301Aug 03 04:45 PM
Curran TerrieSee remarksAug 01Option Exercise0.001,50006,210Aug 02 04:38 PM
KELLOGG PETER NSee RemarksAug 01Option Exercise0.0060,000070,833Aug 02 04:37 PM
Smith Scott AndrewSee RemarksJul 28Option Exercise0.005,000045,415Aug 01 05:34 PM
PEHL MICHAEL F.See remarksJul 28Option Exercise0.002,50003,488Aug 01 04:56 PM
HUGIN ROBERT Jsee remarksJul 28Option Exercise0.0044,50001,021,159Aug 01 04:52 PM
Alles Mark JSee RemarksJul 28Option Exercise0.004,2000175,120Aug 01 04:48 PM